J. Clin. Oncol. 2015-10-01
Phase III Trial to Compare Adjuvant Chemotherapy With Capecitabine and Cisplatin Versus Concurrent Chemoradiotherapy in Gastric Cancer: Final Report of the Adjuvant Chemoradiotherapy in Stomach Tumors Trial, Including Survival and Subset Analyses.
Abstract
Purpose
The Adjuvant Chemoradiotherapy in Stomach Tumors (ARTIST) trial tested whether the addition of radiotherapy to adjuvant chemotherapy improved disease-free survival (DFS) in patients with D2-resected gastric cancer (GC).
Patients and methods
Between November 2004 and April 2008, 458 patients with GC who received gastrectomy with D2 lymph node dissection were randomly assigned to either six cycles of adjuvant chemotherapy with capecitabine and cisplatin (XP) or to two cycles of XP followed by chemoradiotherapy and then two additional cycles of XP (XPRT). This final update contains the first publication of overall survival (OS), together with updated DFS and subset analyses.
Results
With 7 years of follow-up, DFS remained similar between treatment arms (hazard ratio [HR], 0.740; 95% CI, 0.520 to 1.050; P=.0922). OS also was similar (HR, 1.130; 95% CI, 0.775 to 1.647; P=.5272). The effect of the addition of radiotherapy on DFS and OS differed by Lauren classification (interaction P=.04 for DFS; interaction P=.03 for OS) and lymph node ratio (interaction P<.01 for DFS; interaction P<.01 for OS). Subgroup analyses also showed that chemoradiotherapy significantly improved DFS in patients with node-positive disease and with intestinal-type GC. There was a similar trend for DFS and OS by stage of disease.
Conclusion
In D2-resected GC, both adjuvant chemotherapy and chemoradiotherapy are tolerated and equally beneficial in preventing relapse. Because results suggest a significant DFS effect of chemoradiotherapy in subsets of patients, the ARTIST 2 trial evaluating adjuvant chemotherapy and chemoradiotherapy in patients with node-positive, D2-resected GC is under way.
Related Questions
What is the role of adjuvant radiation for gastric cancer found to be locally advanced after up-front surgery in the setting of <D2 but R0 resection?
I think one has to be very careful making blanket statements regarding management of the type of tumor described. The only real data supporting the standard use of RT in virtually all of these patients was the Macdonald trial from a couple of decades ago (and the patients were often treated three de...
Would you ever recommend post-op CRT for gastric adenocarcinoma treated with upfront surgery and D2 resection with R0?
I would agree that chemotherapy without radiation is the current standard of care. INT-0116 notwithstanding, the ARTIST trial did not show a benefit to chemoradiation over chemotherapy alone. An unplanned subset analysis suggested a benefit to radiation in node-positive patients. The subsequent ARTI...
How do you manage a patient with gastric/GE junction carcinoma who has positive lymph nodes at resection after neoadjuvant chemotherapy?
So, we know from the review of the MAGIC study by Dr. Smyth that ypN+ tumors are associated with a worse prognosis than ypN0 tumors. However, there doesn't seem to be anything we can clearly do about it with standard options:1) Changing chemotherapy is not likely to be helpful. Phase III studies in ...